Sven Rohmann, a medical doctor and biotech executive, has been appointed chief executive of Immunicum AB to lead clinical development of the Swedish company’s cell-based therapy for cancer. Dr Rohmann replaces the interim CEO Alex Karlsson-Parra who will return to the job of chief scientific officer. Dr Rohmann joins Immunicum from Oasmia Pharmaceutical AB where he was acting CEO and oversaw the launch of the ovarian cancer drug Apealea. Earlier in his career, he was the founding CEO of Ganymed Pharmaceuticals, acquired by Astellas Pharma Inc in 2016. Dr Rohmann received his MD from the University of Mainz, Germany; a PhD in medicine from Erasmus University in Rotterdam, the Netherlands; and an MBA from the Kellogg School of Management in the US.
Immunicum announced the appointment on 28 August 2020.
Copyright 2020 Evernow Publishing Ltd